Saturday, December 11, 2021 6:31:59 AM
She presented the statical at Utah with external validation of positive and negative trials. She then went on in May and Mt.Sinai to presnt the model and SAP analysis overview with many forward looking statements about how to think about combing agents with DCVax with a couple case studies. In late summer, she told colleagues to save tissue at patient expense cryogenically frozen rather than paraffin as paraffin will make tissue unsable. Can pretty much guarantee the paper was submitted before this. So LL has seen data and continues to speak positively with expectations to have drug in the hands of other soon. PERIOD
UK and EMEA have approved these endpoints and production capability is ramping up. The 10Q alluded to Franhouffer still being in the mix and we all see Advent nearly done building out an workforce and should receive certification correcting after minor issues loke hiring a fre more people. This tells you 30-40% world revenue will soon be approve.
Flashworks per DI is preparing to do comparability studies with Flashworks which should be all that is necessary to get that to the finish line. This is not an efficacy comparison. My guess is they will need to show similar cytokine profiles on testing and safety of one or two doses in volunteers, probaly in the neighborhood of 20-30 GBM patients. Enrollment by AK et al in UK will be fast. That will not take long at all. That too is “coming soon”. UK/EU is in the bag and it certainly seems that submission there has begun due to the Swaton process for CGMP manufacturing approval.
This all creates revenue in 2022. So how then are we dropping like this. Serious money coming soon there.
On top of that, CRL is already approved for production in US & Canada. Ther is some questions of contracts here, but they too were alluded to as a manufacturer in a recent 10Q. After MT. SINAI, it was clear that the US application could be completed soon. People assume no news means they have not submitted the final data package. I think this is absolutely crazy and that the publication is a smokescreen for this, but absolutely real and on track to be ‘coming soon.’ This is all doubted based on CT.gov not getting updated, really? What of they drop that shoe before Cert and everything else?
Meanwhile they take out a full page add at ABTA which meets the limits of possible coming soon campaigns and remove their exhibit booths that would cross that line if not altered.
Your choice here is that everything is moving forward positively with regulators or that LL and UCLA are implicated in a criminal conspiracy case. Cases can be lost but this is what LL and LP would be conspiring to do along with others. The later is cuckoo bananas, bat $hit crazy.
This ‘bear raid’ is seen in many small biotech as big news is pending. I may have clarity on releasing my powder again soon and I love these prices.
That is how I see the present and near future worl which amounts to Orbis or Orbis like approval in the next several weeks.
FDA rushed to get SPINRAZA on Dec 23 to be ahead of Christmas holiday. That drug is different in many ways, like being a pediatric drug for an orphan disease, that is fatal and in some within months or others who melt away in fromt of their parents over years. They rushed to get er done in about four months.
Just what would they do here? Is what I call a coming soon campiagn happening bc that timeline project Jan-Feb approval in US.
Recent NWBO News
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/31/2025 09:23:24 PM
FEATURED Cannabix Technologies Announces Commercial Launch of Marijuana Breath Test (MBT) • Mar 16, 2026 8:37 AM
Record Gold Prices Reshape Economics of New Mine Development • KGC • Mar 16, 2026 9:00 AM
Exxe Group Advances Platform Strategy and Share Structure Reduction Following Strategic Meetings • AXXA • Mar 11, 2026 1:03 PM
DRCR Pushes Forward With Implementation of 2026 Business Plan • DRCR • Mar 11, 2026 12:26 PM
Record Gold Prices Reshape Opportunities for Emerging Producers • LFLR • Mar 11, 2026 9:00 AM
C2 Blockchain Reports 803 Million DOG (Bitcoin) Holdings Following Strategic Accumulation of Bitcoin-Native Digital Assets • CBLO • Mar 10, 2026 8:00 AM
